About Us
Zonsen PepLib Biotech Inc.
Zonsen PepLib Biotech Inc. is an innovative biotechnology company dedicated to the discovery and development of novel peptide-based therapeutics aimed at improving treatment options for patients worldwide. Founded in September 2017, PepLib is headquartered in Zhuzhou, China, with operations in Changsha, China, and a subsidiary in New Jersey, USA. PepLib employs more than 200 people, over 80% of whom are engaged in research and development.
PepLib closed its Series A financing round of CNY 100 million in December 2019, followed by a Series A+ financing round of CNY 220 million in April 2021. Most recently, the company secured nearly CNY 100 million through its Series B financing round in July 2025.
To date, PepLib has secured R&D collaboration agreements with leading pharmaceutical enterprises, including Novartis,AstraZeneca, Jiudian Pharmaceutical and Kanion Pharmaceutical, among others.
PepLib has established a robust and diverse suite of proprietary peptide libraries and discovery capabilities, with a primary therapeutic focus in oncology and cardiometabolic diseases. PepLib’s platforms support multiple peptide-based modalities, including peptide radionuclide conjugates (PRCs), peptide oligonucleotide conjugates (POCs), and peptide drug conjugates (PDCs).
R&D Input
Accumulated R&D input of approximately 380 million yuan, with 600 million yuan expected to be invested in the next 3 years.
New Drug Milestone Service + Self-developed Pipelines.
.
Company Appearance
FLIPR tetra
Biotek Cytation10
Biotek Cytation5
Biotek Synergy neo2
PepLib aims to promote the development and accessibility of innovative peptide drugs, benefiting global patients and human health while keeping costs low.
Copyright©2023 Zonsen PepLib Biotech Inc. This website supports IPV6
